Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.

Research paper from Europe PMC. Evidence status: source reported.

Published

2021-06-23

Source reference

MED:34174193

DOI

10.1016/s1473-3099(21)00289-9

Jurisdiction

Not assessed

Licence

Bibliographic metadata only; article rights retained

Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, Fuller C, Irwin-Singer A, Davies D, Tut G, Lopez Bernal J, Moss P, Hayward A, Copas A, Shallcross L. · Lancet Infect Dis · research support, non-u.s. gov't; research-article; journal article · Found via: ClinicalTrials.gov result publication

Source: https://europepmc.org/article/MED/34174193. Captured 2026-10-29.

Limitations: Listed by a ClinicalTrials.gov registration as a result publication of that study, and fetched by its PubMed ID. The registry's listing is the sponsor's statement; it does not confirm which data the paper used. Preprints may not be peer reviewed.